

DT13 Rec'd PCT/STO 16 FEB 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Hans-Juergen Krause et al.
PCT Application No.	PCT/IB2003/004502
PCT Filing Date:	15 August 2003
U.S. Serial No.:	(not yet assigned)
Filed:	(concurrently herewith)
Priority Date:	16 August 2002
Entitled:	FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF- $\alpha$ ASSOCIATED DISORDERS

ART UNIT: (not yet assigned)

EXAMINER: (not yet assigned)

Attorney Docket No.: BBC-166

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EU509624024US, in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

February 16, 2005  
Date

  
Lisa Rasmussen

**Transmittal of Sequence Listing, Computer Readable Form, and Amendment Pertaining  
Thereeto For Invention Containing Nucleotide and/or Amino Acid Sequence  
Under 37 CFR §§1.821-1.825**

Sir:


Transmitted herewith please find: a diskette containing a computer readable form (CRF) copy of the Sequence Listing, and a paper copy of the Sequence Listing for the patent application filed currently herewith this paper.

Applicants have assigned a separate identifier to each of the 34 sequences disclosed, as required by 37 CFR §§1.821-1.825.

Applicants verify the following:

1. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.821(f);
2. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application contain no new matter and do not go beyond the original disclosure of the application, as required by 37 CFR §1.821(g);
3. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,



John D. Conway  
Registration No. 39,150  
Attorney for Applicants  
Abbott Bioresearch Center  
telephone: (508) 688-8046  
telefax: (508) 688-8110